Member Info for pomander

on this board to a simple conversation between myself and rivotman is bizarre and displays serious signs of paranoia. My conversation with rivotman was cordial on both sides and yet others felt the need to jump in purely to insult me because I don't believe the C-Diff program has the sort of value being touted on here. Welcome to The Peoples Republic of China. If Glyn had 3 commercial contracts lined up that he could sign today, that would suggest to me that they were not offering a particularly attractive terms, although I am not exactly sure what the term 'contact ' means in this context as is very wide term.

My sincerest apologies for making a handful of post on your private board - albeit directed to Rivotman who I know from another board. I have not said the CEO is lying, my reference was to the financial reports so as you are the one lying I am afraid no recommend from me. I do understand your hostility, repeating the same message ad nasueam on an industrial scale with no results must get a little frustrating but all good things come to those that wait. Google alerts are handy though.

Totally meaningless comparison and not the purpose of this BB. Entry and exit points are key.

ego - no idea what you are talking about, I agree mkt does not precisely value every stock or there would be no money to be made. All I am saying is that if Summ's C-Diff program had potential this would be more reasonably reflected in the share price by now.

Ok conference call, that is different to financial reports and yo are right I did not like the Sarepta deal - I think it was driven by a combination Summ running out of cash and a cheap hedge for Sarepta shareholders as it own drug hit problems. I wish everyone well.

Rivotman- As Jim O'Neil as well as many others have pointed out Antibiotic resistance is indeed a ticking time bomb that could create catastrophic financial and economic implications globally and yet big pharma disinterested. https://amr-review.org/sites/default/files/160518_Final%20paper_with%20cover.pdf is worth reading and will put things into perspective. I don't dislike Sarepta, like everyone I wish for a cure for what is a horrible disease but the odds are stacked against this, but this does not mean the scientists should give up. Not sure where it states in the last annual report that he had a number of commercial contracts that he could sign today. ? Not my understanding. Incidentally JM has said that the C-Diff programme is small fry compared to DMD- maybe that's a positive ! I maintain a small holding in Summ and I would invest further if any sign of interest in their C-Diff program and indeed any change in the antibiotic resistance space generally. Fortunately at Plethora - they have the only approved drug for a condition affecting a huge potential market.

The peak sales part is in the ball park, the rest is highly questionable. Securing 50% of market is very unlikely and for small pharma's like Summ finding a license partner is the holy grail. Any sale would be on distressed terms, unless an auction could be created as Summ cannot bring a drug to market, it has no sales network or infrastructure to do so. Summ has a very good drug but unfortunately C-Diff is a very unloved sector by big-pharma as commercial returns and other factors make it very unattractive. I suspect this explains why Summ has been unable to date to secure a partner or sell the program. The share price would also seem to reflect this- Summ has been promoted far and wide.

SP7 - RP had the option within original funding arrangement to waive the milestone requirements. I don't think JM is trying to dump DBC into LIFE - I think he wants it out of RP and to remain in control as it is very much his baby. If an arrangement to issue shares in LIFE directly to RP shareholders on a pro rate basis to their holdings in RP was made now this would signal a takeover in play at RP which must be avoided until a formal offer is made to all shareholders. Its all admittedly speculative, but I find announcing an intention to buy a company and then delaying the formal offer for shareholders to approve in the hope that the target gains traction is a rather tenuous one, but who knows! Good luck to you whatever the eventual outcome.

Can anyone else come up with a good reason for the delay in getting a formal offer out for LIFE shareholders to approve? 1) The surrendering of the funding arrangement for DBC is not a good deal for RP shareholders as it surrendered the future allocation of shares on very favourable terms, so there must be good reason for the funding agreement to have been ripped up and only a few months after its inception and fanfare of announcement. It could not have been in their thinking then, so something major has changed that. The acquisition of DBC by LIFE does not eliminate RP shareholders entirely from participating in the expected commercial success of DBC as RP will still hold shares in DBC as that will effectively become LIFE as a 100% wholly owned subsidiary. However , the acquisition of DBC by LIFE creates a mechanism whereby RP shareholders cam receive their allocation of LIFE shares directly in proportion to their percentage holdings in RP, thus removing it from RP’s balance sheet. This would also explain the delay in the LIFE transaction as it is dependent upon the sale of RP. I can see no reason for it to have taken so far 3 1/2 months to get a formal offer out to shareholders to approve– the Ple acquisition was much quicker.

SP& - Thanks for the good wishes - I see the share allotment was due to warrants and the convertible loan notes, so clears that one up ! Thinking about the change of accounting period, might it just be to match that of LIFE for ease of consolidation ? Numbers to 31 Dec would be needed for any prospectus, but not sure this would necessarily cause you to change your accounting period ''at this time'' although it makes sense for a holding company to have the same year end as its subsidiary going forwards. If JM follows a past pattern it will be a professional valuation report in the prospectus that determines a fair market value for The DBC this may be biggest cause for the delay. If the valuation is accepted by the market, the share price of LIFE theoretically remains the same ( for example- issue £15m worth of new shares for an asset valued at £15m = no change in share price) although of course this rarely happens in reality. Good luck to all also - nothing more frustrating than holding a suspended share in a vacuum of information.

saintpeter I suspect the acquisition will be via a scheme of arrangement as this gives better certainty of outcome. The formal offer must go out within 28 days of being made, shareholders have 21 days to consider and there is a further 14 days once it is unconditional. I am not a corporate lawyer but if the RTO has to complete by 5th April to satisfy AIM rules we must be close to further developments and certainly looks like that is also behind the accounting period change as you say..

clueless - you can do better on your own.

GMCC- instead of making childish digs at me at every opportunity might I suggest you contact Alquieme on the Ple board. He is a pharma expert with many years of experience including bringing drugs to market. He will give you the current industry position on C-Diff drugs and his view on RDZ, about which he is fully familiar. I am not a naysayer, my views are not negative or pessimistic, merely realistic in terms of risks and rewards. It is somewhat ironic that you have been pumping out bullish information and comments about this company on an industrial scale for literally years now and you get your knickers in such a twist when someone has the audacity to challenge the status quo. Right now Summ has a C-diff with no takers and a lousy DMD deal (in my view) that it was forced into. Let's hope Glyn and his team can turn it around for the major shareholders are clearly not happy with progress. Glyn himself must be concerned, his own share scheme was predicated upon a share price of a multiple of today's level.

GMCC- I get all that, I am not doubting Ridinilzole potential efficacy as a treatment - the issue facing SUMM is a commercial one linked to the total apathy being shown towards new antibiotics from big-pharma.. Your P3 trial cost estimates were way off base, as was the sample size under any assumptions and SUMM simply cannot bring a drug to market. Its is clearly proving a great challenge is to find a collaborator that is ready, willing and able to fund Ridinizole thorough P3 and a commercial launch through whatever financial mechanism. SUMM may well achieve this, but I don't think it is the slam dunk that many on here seem to believe. New treatments to replace antibiotics are more advanced than you know , you clearly did not bother listen to the Radio 5 Live Since team and the experts on that video/podcast. You are very good at selectively producing reports to promulgate your agenda but as you well know in Science there are always several views on every matter including the speed at which bacteria will mutate to make new antibiotics ineffective. It also just one of the reasons cited as to why big-pharma are disinterested because it restricts the commercial opportunity. This is not a secret, it is widely known and written about. You seem hung up on the 4/5 year time frame I indicated based of what I have read. 10 years wouldn't that be that commercially attractive either and in today's world a year of use is almost the equivalent of a decade from the 1960's on wards. Antibiotics are cheap short duration drugs, big- pharma's focus (sadly) is on long duration expensive drugs If you think big-pharma is interested in anything other than making money as the number one priority you will be very disappointed.

egomonkey- if you wish to engage with, please at least take the time to read and understand what I have said. I asked Freemoney how he knew Summ were in talks with several potential partners. You informed me that this known as Glyn has said so. I responded by saying that it was normal for pharma companies to be in talks. At no point have I ever said that Summ was not in talks, substantive or otherwise. Your agenda is clearly to discredit me by whatever means possible, but I take this as a great compliment as to spend time doing so means that you see foundation of my comments and views. Anyway, time to move on.

Rhines - by referring to one of my many other holdings which has no relevance to the debate here, you simply present yourself to any one with a brain, as a desperate, gratuitously insulting and childish nincompoop incapable of sensible debate. Some might like to consider both the pro's and con's in making a decision.

egomonkey- Your logic is flawed and your comment that ''You say drawing general comparisons is of little use, then you do exactly that'' is untrue as you well know. I suggest you read my post to GMCC and read some of the articles and research for yourself, instead of being lazy and throwing criticisms at me without doing your homework. We know, because ''Glyn said so'' - who is he, the Messiah, how naive are you - pharma's are in talks with one another all the time, its the nature of the industry. Perhaps you should ask why, if Summ is in talks of substance with several potential partners why the share price is half what is was 3 years ago - fair question - eh? The exercise price for the share options are all out of money by a distance and major shareholders voted down the remuneration policy which is most unusual. Perhaps this is what shareholders should be questioning rather than relying on ''Glyn said so''. Arrowhead Pharma, another one of JM's top picks are another ''Glyn said so'', only in that case it was a Vince Anzalone who said so, until it crashed and lost 95% of its value. Every CEO of very Pharma believes he has the next magic treatment, that's the nature of the sector - one slight showing of doubt and the sp gets killed and funding dries up. Its a tricky balancing act. I have not framed it as a disaster story at all, although some might on the back of the woeful share price performance. C-Diff is going to be difficult, speak to anyone in the industry, there is little or no interest currently being shown by Big-Pharma. Most ended their antibiotic programs some time ago. DMD - we can just wait and hope for stellar P2 read outs, but one would be naive to ignore the obvious risks attached to any DMD drug. Billions have been spent and many have come and gone. Its a huge challenge.

I think the inference on time frames is pretty clear from the articles, hence looking at new ways to treat bacteria with viruses that mutate along side them to retain 100% effectiveness. No one is going to or able to give a precise time horizon before a new antibiotic will run into problems, but 4/5 years I think is a reasonable estimate. 4/5 years of use toady is probably equivalent a couple pf decades of use not so very long ago.

egomonkey- it is indeed an interesting board, Free-Money is able to make statements without challenge, all except form me that is, that the company is in talks with several potential partners on its C-Diff program. I don't expect to get an answer. Which of my statements do you find highly misleading? Drawing comparisons with other successful drugs without specifics is of little use. I am not aware of any small cap pharma that has been able to bring a drug to market without partnering of some kind, particularly in recent times where it is an impossibility because of the costs and infrastructure required. Given that Glyn has travelled the globe presenting Summ's C-Diff program and has no doubt approached potential partners, the lack of any progress over a period of some time now must be of some concern. The plan, as many have attested to on here was to off load the C-Diff program to fund the DMD program. Antibiotic resistance creates a potential Armageddon situation in years to come and yet no progress announced to date on a collaboration - I think a very relevant question to ask why, instead of relying on this endless all's rosy garden approach, which by the way has been going on for some years now. The share price is only a barometer of the markets perception of any company's prospects but clearly if you accept this barometer, SUMM has gone less than nowhere in terms of its share price over the last 3 years. Surely that must be a concern?

Despite your pal Trollydoll believing he now speaks for you and all others on this board, which is a dangerous state of affairs in itself particularly given his own horrendous track record of share prediction for Summ I trust you will find the following of use. There are of course differing views to your own on the antibiotics you name, but I think of greater relevance is that the use of antibiotics has exploded such that as many are probably superscribed in a few years as were once prescribed in decades - this concentrates and accelerates the mutation and resistance process thus restricting the useful life of existing and potential new antibiotics. There are other factors causing bacteria to be become more resistant and much quicker which will equally apply to new antibiotics as it is a process not a drug specific issue. This, along with the fact that big -pharma for commercial reasons prefers high cots drugs that patients will likely remain on for the rest of their lives over short duration ,low cost drugs such as antibiotics is dampening their interest and this is widely known and accepted within the industry. The 5 Live Science interviews by the Naked Scientists Team (B) are particularly useful as they tend to be very current and cutting edge. I have included a fairly list of links to other various articles, some of which I am sure you may have seen. A) http://www.thenakedscientists.com/articles/interviews/giving-germs-cold-their-own http://www.thenakedscientists.com/podcasts/naked-scientists/when-drugs-dont-work How bugs become resistant to drugs B)http://www.telegraph.co.uk/science/2016/03/14/first-new-antibiotic-in-30-years-discovered-in-major-breakthroug/ http://www.independent.co.uk/news/science/antibiotic-resistance-new-drug-nose-mrsa-superbugs-lugdunin- a7160131.html www.sciencedaily.com/terms/antibiotic_resistance.htm http://evolution.berkeley.edu/evolibrary/news/080401_mrsa http://www.digitaltrends.com/cool-tech/timelapse-bacteria-resistance/